Nordea Investment Management AB Acquires 1,286 Shares of Axon Enterprise, Inc $AXON

Nordea Investment Management AB lifted its stake in Axon Enterprise, Inc (NASDAQ:AXON) by 12.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,624 shares of the biotechnology company’s stock after purchasing an additional 1,286 shares during the period. Nordea Investment Management AB’s holdings in Axon Enterprise were worth $6,657,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Axon Enterprise by 4.2% in the third quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock worth $6,684,217,000 after buying an additional 376,904 shares in the last quarter. Jennison Associates LLC lifted its position in shares of Axon Enterprise by 53.8% during the 3rd quarter. Jennison Associates LLC now owns 943,944 shares of the biotechnology company’s stock valued at $677,412,000 after buying an additional 330,213 shares in the last quarter. Norges Bank purchased a new position in shares of Axon Enterprise during the 2nd quarter valued at about $637,806,000. Northern Trust Corp grew its stake in shares of Axon Enterprise by 1.6% during the 3rd quarter. Northern Trust Corp now owns 743,926 shares of the biotechnology company’s stock valued at $533,871,000 after acquiring an additional 11,726 shares during the period. Finally, 1832 Asset Management L.P. increased its holdings in Axon Enterprise by 129.2% in the 2nd quarter. 1832 Asset Management L.P. now owns 536,420 shares of the biotechnology company’s stock worth $444,124,000 after acquiring an additional 302,420 shares in the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

AXON has been the topic of a number of recent analyst reports. Craig Hallum restated a “buy” rating and set a $820.00 target price on shares of Axon Enterprise in a research note on Wednesday, February 25th. Needham & Company LLC reduced their price objective on shares of Axon Enterprise from $870.00 to $600.00 and set a “buy” rating for the company in a research note on Friday, February 20th. UBS Group lowered their target price on shares of Axon Enterprise from $610.00 to $570.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 25th. Royal Bank Of Canada dropped their target price on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating for the company in a report on Wednesday, February 25th. Finally, Citigroup reiterated a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, February 25th. Sixteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Axon Enterprise has an average rating of “Moderate Buy” and an average target price of $762.93.

Axon Enterprise Trading Down 2.1%

Shares of AXON opened at $450.46 on Friday. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.53 and a quick ratio of 2.29. Axon Enterprise, Inc has a 1 year low of $396.41 and a 1 year high of $885.91. The company has a 50 day simple moving average of $506.17 and a two-hundred day simple moving average of $594.01. The firm has a market cap of $36.22 billion, a P/E ratio of 296.36, a price-to-earnings-growth ratio of 9.82 and a beta of 1.46.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.55. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The firm had revenue of $796.72 million for the quarter, compared to analysts’ expectations of $755.29 million. During the same quarter last year, the business posted $2.08 earnings per share. The company’s revenue for the quarter was up 38.5% compared to the same quarter last year. On average, equities analysts expect that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Axon Enterprise news, insider Isaiah Fields sold 2,000 shares of the business’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $535.01, for a total value of $1,070,020.00. Following the sale, the insider owned 55,588 shares in the company, valued at $29,740,135.88. The trade was a 3.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $500.24, for a total transaction of $5,002,400.00. Following the transaction, the chief executive officer directly owned 3,090,997 shares of the company’s stock, valued at $1,546,240,339.28. This trade represents a 0.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 23,855 shares of company stock worth $13,299,928 in the last 90 days. 4.40% of the stock is owned by company insiders.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.